Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

The mGlu7 receptor provides protective effects against epileptogenesis and epileptic seizures.

Girard B, Tuduri P, Moreno MP, Sakkaki S, Barboux C, Bouschet T, Varrault A, Vitre J, McCort-Tranchepain I, Dairou J, Acher F, Fagni L, Marchi N, Perroy J, Bertaso F.

Neurobiol Dis. 2019 Sep;129:13-28. doi: 10.1016/j.nbd.2019.04.016. Epub 2019 Apr 30.

PMID:
31051234
2.

Chloride ions stabilize the glutamate-induced active state of the metabotropic glutamate receptor 3.

Tora AS, Rovira X, Cao AM, Cabayé A, Olofsson L, Malhaire F, Scholler P, Baik H, Van Eeckhaut A, Smolders I, Rondard P, Margeat E, Acher F, Pin JP, Goudet C.

Neuropharmacology. 2018 Sep 15;140:275-286. doi: 10.1016/j.neuropharm.2018.08.011. Epub 2018 Aug 11.

PMID:
30102917
3.

Profiling of orthosteric and allosteric group-III metabotropic glutamate receptor ligands on various G protein-coupled receptors with Tag-lite® assays.

Belhocine A, Veglianese P, Hounsou C, Dupuis E, Acher F, Durroux T, Goudet C, Pin JP.

Neuropharmacology. 2018 Sep 15;140:233-245. doi: 10.1016/j.neuropharm.2018.07.032. Epub 2018 Aug 9.

PMID:
30099051
4.

Mutual activation of glutamatergic mGlu4 and muscarinic M4 receptors reverses schizophrenia-related changes in rodents.

Cieślik P, Woźniak M, Rook JM, Tantawy MN, Conn PJ, Acher F, Tokarski K, Kusek M, Pilc A, Wierońska JM.

Psychopharmacology (Berl). 2018 Oct;235(10):2897-2913. doi: 10.1007/s00213-018-4980-y. Epub 2018 Jul 27.

5.

Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites.

Selvam C, Lemasson IA, Brabet I, Oueslati N, Karaman B, Cabaye A, Tora AS, Commare B, Courtiol T, Cesarini S, McCort-Tranchepain I, Rigault D, Mony L, Bessiron T, McLean H, Leroux FR, Colobert F, Daniel H, Goupil-Lamy A, Bertrand HO, Goudet C, Pin JP, Acher FC.

J Med Chem. 2018 Mar 8;61(5):1969-1989. doi: 10.1021/acs.jmedchem.7b01438. Epub 2018 Feb 14.

PMID:
29397723
6.

Pharmacological activation of mGlu4 and mGlu7 receptors, by LSP2-9166, reduces ethanol consumption and relapse in rat.

Lebourgeois S, Vilpoux C, Jeanblanc J, Acher F, Marie N, Noble F, Naassila M.

Neuropharmacology. 2018 May 1;133:163-170. doi: 10.1016/j.neuropharm.2018.01.031. Epub 2018 Jan 31.

PMID:
29378211
7.

Role of mGlu7 receptor in morphine rewarding effects is uncovered by a novel orthosteric agonist.

Hajasova Z, Canestrelli C, Acher F, Noble F, Marie N.

Neuropharmacology. 2018 Mar 15;131:424-430. doi: 10.1016/j.neuropharm.2018.01.002. Epub 2018 Jan 4.

PMID:
29307544
8.

Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4.

Zussy C, Gómez-Santacana X, Rovira X, De Bundel D, Ferrazzo S, Bosch D, Asede D, Malhaire F, Acher F, Giraldo J, Valjent E, Ehrlich I, Ferraguti F, Pin JP, Llebaria A, Goudet C.

Mol Psychiatry. 2018 Mar;23(3):509-520. doi: 10.1038/mp.2016.223. Epub 2016 Dec 20.

PMID:
27994221
9.

Neurochemical and behavioral studies on the 5-HT1A-dependent antipsychotic action of the mGlu4 receptor agonist LSP4-2022.

Woźniak M, Gołembiowska K, Noworyta-Sokołowska K, Acher F, Cieślik P, Kusek M, Tokarski K, Pilc A, Wierońska JM.

Neuropharmacology. 2017 Mar 15;115:149-165. doi: 10.1016/j.neuropharm.2016.06.025. Epub 2016 Jul 25.

PMID:
27465045
10.

Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network.

Tassin V, Girard B, Chotte A, Fontanaud P, Rigault D, Kalinichev M, Perroy J, Acher F, Fagni L, Bertaso F.

Front Neural Circuits. 2016 Apr 25;10:31. doi: 10.3389/fncir.2016.00031. eCollection 2016.

11.

Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022.

Woźniak M, Acher F, Marciniak M, Lasoń-Tyburkiewicz M, Gruca P, Papp M, Pilc A, Wierońska JM.

Curr Neuropharmacol. 2016;14(5):413-26.

12.

Allosteric modulation of metabotropic glutamate receptors by chloride ions.

Tora AS, Rovira X, Dione I, Bertrand HO, Brabet I, De Koninck Y, Doyon N, Pin JP, Acher F, Goudet C.

FASEB J. 2015 Oct;29(10):4174-88. doi: 10.1096/fj.14-269746. Epub 2015 Jun 26.

PMID:
26116702
13.

A novel mGlu4 selective agonist LSP4-2022 increases behavioral despair in mouse models of antidepressant action.

Podkowa K, Rzeźniczek S, Marciniak M, Acher F, Pilc A, Pałucha-Poniewiera A.

Neuropharmacology. 2015 Oct;97:338-45. doi: 10.1016/j.neuropharm.2015.05.039. Epub 2015 Jun 12.

PMID:
26074092
14.

Two-photon "caging" groups: effect of position isomery on the photorelease properties of aminoquinoline-derived photolabile protecting groups.

Tran C, Gallavardin T, Petit M, Slimi R, Dhimane H, Blanchard-Desce M, Acher FC, Ogden D, Dalko PI.

Org Lett. 2015 Feb 6;17(3):402-5. doi: 10.1021/ol5035035. Epub 2015 Jan 27.

PMID:
25625881
15.

Therapeutic potential of group III metabotropic glutamate receptor ligands in pain.

Acher F, Goudet C.

Curr Opin Pharmacol. 2015 Feb;20:64-72. doi: 10.1016/j.coph.2014.11.007. Epub 2014 Dec 10. Review.

PMID:
25498980
16.

Determination of the absolute configuration of phosphinic analogues of glutamate.

Commare B, Rigault D, Lemasson IA, Deschamps P, Tomas A, Roussel P, Brabet I, Goudet C, Pin JP, Leroux FR, Colobert F, Acher FC.

Org Biomol Chem. 2015 Jan 28;13(4):1106-12. doi: 10.1039/c4ob01960a. Epub 2014 Nov 24.

PMID:
25417857
17.

Molecular determinants of agonist selectivity in glutamate-gated chloride channels which likely explain the agonist selectivity of the vertebrate glycine and GABAA-ρ receptors.

Blarre T, Bertrand HO, Acher FC, Kehoe J.

PLoS One. 2014 Sep 26;9(9):e108458. doi: 10.1371/journal.pone.0108458. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e115788.

18.

Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7.

Jalan-Sakrikar N, Field JR, Klar R, Mattmann ME, Gregory KJ, Zamorano R, Engers DW, Bollinger SR, Weaver CD, Days EL, Lewis LM, Utley TJ, Hurtado M, Rigault D, Acher F, Walker AG, Melancon BJ, Wood MR, Lindsley CW, Conn PJ, Xiang Z, Hopkins CR, Niswender CM.

ACS Chem Neurosci. 2014 Dec 17;5(12):1221-37. doi: 10.1021/cn500153z. Epub 2014 Oct 9.

19.

Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist.

Cajina M, Nattini M, Song D, Smagin G, Jørgensen EB, Chandrasena G, Bundgaard C, Toft DB, Huang X, Acher F, Doller D.

ACS Med Chem Lett. 2013 Dec 12;5(2):119-23. doi: 10.1021/ml400338f. eCollection 2014 Feb 13.

20.

Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.

Favre-Besse FC, Poirel O, Bersot T, Kim-Grellier E, Daumas S, El Mestikawy S, Acher FC, Pietrancosta N.

Eur J Med Chem. 2014 May 6;78:236-47. doi: 10.1016/j.ejmech.2014.03.056. Epub 2014 Mar 18.

PMID:
24686010
21.

Alleviating pain hypersensitivity through activation of type 4 metabotropic glutamate receptor.

Vilar B, Busserolles J, Ling B, Laffray S, Ulmann L, Malhaire F, Chapuy E, Aissouni Y, Etienne M, Bourinet E, Acher F, Pin JP, Eschalier A, Goudet C.

J Neurosci. 2013 Nov 27;33(48):18951-65. doi: 10.1523/JNEUROSCI.1221-13.2013.

22.

Tandem triad systems based on FRET for two-photon induced release of glutamate.

Picard S, Cueto-Diaz EJ, Genin E, Clermont G, Acher F, Ogden D, Blanchard-Desce M.

Chem Commun (Camb). 2013 Nov 28;49(92):10805-7. doi: 10.1039/c3cc45812a.

PMID:
24108351
23.

The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.

Wierońska JM, Acher FC, Sławińska A, Gruca P, Lasoń-Tyburkiewicz M, Papp M, Pilc A.

Psychopharmacology (Berl). 2013 Jun;227(4):711-25. doi: 10.1007/s00213-013-3005-0. Epub 2013 Mar 10.

24.

Variations on glutamate binding in channel-gated receptors.

Acher FC.

Structure. 2013 Mar 5;21(3):317-9. doi: 10.1016/j.str.2013.02.012.

25.

Substitution effect on the one- and two-photon sensitivity of DMAQ "caging" groups.

Petit M, Tran C, Roger T, Gallavardin T, Dhimane H, Palma-Cerda F, Blanchard-Desce M, Acher FC, Ogden D, Dalko PI.

Org Lett. 2012 Dec 21;14(24):6366-9. doi: 10.1021/ol3031704. Epub 2012 Dec 6.

PMID:
23214948
26.

Synthesis of quinoline dicarboxylic esters as biocompatible fluorescent tags.

Laras Y, Hugues V, Chandrasekaran Y, Blanchard-Desce M, Acher FC, Pietrancosta N.

J Org Chem. 2012 Sep 21;77(18):8294-302. Epub 2012 Sep 12.

PMID:
22931204
27.

Role of mGluR4 in acquisition of fear learning and memory.

Davis MJ, Iancu OD, Acher FC, Stewart BM, Eiwaz MA, Duvoisin RM, Raber J.

Neuropharmacology. 2013 Mar;66:365-72. doi: 10.1016/j.neuropharm.2012.07.038. Epub 2012 Aug 2.

28.

Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.

Amalric M, Lopez S, Goudet C, Fisone G, Battaglia G, Nicoletti F, Pin JP, Acher FC.

Neuropharmacology. 2013 Mar;66:53-64. doi: 10.1016/j.neuropharm.2012.05.026. Epub 2012 Jun 1. Review.

PMID:
22664304
29.

Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs.

Flor PJ, Acher FC.

Biochem Pharmacol. 2012 Aug 15;84(4):414-24. doi: 10.1016/j.bcp.2012.04.013. Epub 2012 Apr 24. Review.

PMID:
22554564
30.

Successful prediction of substrate-binding pocket in SLC17 transporter sialin.

Pietrancosta N, Anne C, Prescher H, Ruivo R, Sagné C, Debacker C, Bertrand HO, Brossmer R, Acher F, Gasnier B.

J Biol Chem. 2012 Mar 30;287(14):11489-97. doi: 10.1074/jbc.M111.313056. Epub 2012 Feb 13.

31.

Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors.

Fazio F, Lionetto L, Molinaro G, Bertrand HO, Acher F, Ngomba RT, Notartomaso S, Curini M, Rosati O, Scarselli P, Di Marco R, Battaglia G, Bruno V, Simmaco M, Pin JP, Nicoletti F, Goudet C.

Mol Pharmacol. 2012 May;81(5):643-56. doi: 10.1124/mol.111.074765. Epub 2012 Feb 6.

PMID:
22311707
32.

A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential.

Goudet C, Vilar B, Courtiol T, Deltheil T, Bessiron T, Brabet I, Oueslati N, Rigault D, Bertrand HO, McLean H, Daniel H, Amalric M, Acher F, Pin JP.

FASEB J. 2012 Apr;26(4):1682-93. doi: 10.1096/fj.11-195941. Epub 2012 Jan 5.

PMID:
22223752
33.

Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.

Wierońska JM, Stachowicz K, Acher F, Lech T, Pilc A.

Psychopharmacology (Berl). 2012 Apr;220(3):481-94. doi: 10.1007/s00213-011-2502-2. Epub 2011 Sep 28.

34.

Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.

Lopez S, Bonito-Oliva A, Pallottino S, Acher F, Fisone G.

J Parkinsons Dis. 2011;1(4):339-46. doi: 10.3233/JPD-2011-11066.

PMID:
23939343
35.

Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems.

Wierońska JM, Stachowicz K, Pałucha-Poniewiera A, Acher F, Brański P, Pilc A.

Neuropharmacology. 2010 Dec;59(7-8):627-34. doi: 10.1016/j.neuropharm.2010.08.008. Epub 2010 Aug 14.

PMID:
20713068
36.

Rose Bengal analogs and vesicular glutamate transporters (VGLUTs).

Pietrancosta N, Kessler A, Favre-Besse FC, Triballeau N, Quentin T, Giros B, El Mestikawy S, Acher FC.

Bioorg Med Chem. 2010 Sep 15;18(18):6922-33. doi: 10.1016/j.bmc.2010.06.069. Epub 2010 Jun 25.

PMID:
20708942
37.

Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach.

Mony L, Triballeau N, Paoletti P, Acher FC, Bertrand HO.

Bioorg Med Chem Lett. 2010 Sep 15;20(18):5552-8. doi: 10.1016/j.bmcl.2010.07.043. Epub 2010 Jul 15.

PMID:
20692832
38.

A critical pocket close to the glutamate binding site of mGlu receptors opens new possibilities for agonist design.

Acher FC, Selvam C, Pin JP, Goudet C, Bertrand HO.

Neuropharmacology. 2011 Jan;60(1):102-7. doi: 10.1016/j.neuropharm.2010.07.002. Epub 2010 Jul 16.

PMID:
20621106
39.

A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists.

Selvam C, Oueslati N, Lemasson IA, Brabet I, Rigault D, Courtiol T, Cesarini S, Triballeau N, Bertrand HO, Goudet C, Pin JP, Acher FC.

J Med Chem. 2010 Apr 8;53(7):2797-813. doi: 10.1021/jm901523t.

PMID:
20218620
40.

Aplysia cys-loop glutamate-gated chloride channels reveal convergent evolution of ligand specificity.

Kehoe J, Buldakova S, Acher F, Dent J, Bregestovski P, Bradley J.

J Mol Evol. 2009 Aug;69(2):125-41. doi: 10.1007/s00239-009-9256-z. Epub 2009 Jun 25.

PMID:
19554247
41.

Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism.

Beurrier C, Lopez S, Révy D, Selvam C, Goudet C, Lhérondel M, Gubellini P, Kerkerian-LeGoff L, Acher F, Pin JP, Amalric M.

FASEB J. 2009 Oct;23(10):3619-28. doi: 10.1096/fj.09-131789. Epub 2009 Jun 12.

PMID:
19525404
42.

Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment.

Cuomo D, Martella G, Barabino E, Platania P, Vita D, Madeo G, Selvam C, Goudet C, Oueslati N, Pin JP, Acher F, Pisani A, Beurrier C, Melon C, Kerkerian-Le Goff L, Gubellini P.

J Neurochem. 2009 May;109(4):1096-105. doi: 10.1111/j.1471-4159.2009.06036.x. Epub 2009 Mar 14.

43.

High-potency olfactory receptor agonists discovered by virtual high-throughput screening: molecular probes for receptor structure and olfactory function.

Triballeau N, Van Name E, Laslier G, Cai D, Paillard G, Sorensen PW, Hoffmann R, Bertrand HO, Ngai J, Acher FC.

Neuron. 2008 Dec 10;60(5):767-74. doi: 10.1016/j.neuron.2008.11.014.

44.

Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors.

Mony L, Krzaczkowski L, Leonetti M, Le Goff A, Alarcon K, Neyton J, Bertrand HO, Acher F, Paoletti P.

Mol Pharmacol. 2009 Jan;75(1):60-74. doi: 10.1124/mol.108.050971. Epub 2008 Oct 15.

PMID:
18923063
45.

Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile.

Cottyn B, Acher F, Ramassamy B, Alvey L, Lepoivre M, Frapart Y, Stuehr D, Mansuy D, Boucher JL, Vichard D.

Bioorg Med Chem. 2008 Jun 1;16(11):5962-73. doi: 10.1016/j.bmc.2008.04.056. Epub 2008 Apr 26.

PMID:
18502134
46.
47.

Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain.

Goudet C, Chapuy E, Alloui A, Acher F, Pin JP, Eschalier A.

Pain. 2008 Jul;137(1):112-24. Epub 2007 Sep 27.

48.
49.

Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists.

Sibille P, Lopez S, Brabet I, Valenti O, Oueslati N, Gaven F, Goudet C, Bertrand HO, Neyton J, Marino MJ, Amalric M, Pin JP, Acher FC.

J Med Chem. 2007 Jul 26;50(15):3585-95. Epub 2007 Jun 28.

PMID:
17602546
50.

Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.

Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M.

J Neurosci. 2007 Jun 20;27(25):6701-11.

Supplemental Content

Support Center